Keros Therapeutics (NASDAQ:KROS) stock plunged 73% Thursday after the company said it has halted two arms of a Phase 2 clinical study of its drug cibotercept in patients with pulmonary arterial ...

Keros Therapeutics' (NASDAQ:KROS) stock up by 7.5% over the past three months. However, we decided to study the company's mixed-bag of fundamentals to assess what this could mean for future share ...

Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial ...

On Thursday, Keros Therapeutics, Inc. (NASDAQ:KROS) voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial Phase 2 trial of cibotercept (KER-012) in ...

Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, lowering the price forecast from $32 to $18. Zemansky noted that Keros has ...

Dec 12 (Reuters) - Keros Therapeutics (KROS.O), opens new tab said on Thursday it had paused giving patients higher doses of its high blood pressure treatment in a mid-stage study after reports of a ...

TD Cowen downgraded Keros Therapeutics (KROS) to Hold from Buy after the company voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS Phase 2 clinical trial of ...

Fintel reports that on June 10, 2025, B of A Securities downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from Buy to Neutral. Analyst Price Forecast Suggests 89.41% Upside As of June 2, ...

LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...